批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2024/08/26 |
SUPPL-24(补充) |
Approval |
Labeling |
STANDARD
;Orphan
|
|
|
2020/03/16 |
SUPPL-20(补充) |
Approval |
Labeling |
STANDARD
;Orphan
|
|
|
2019/12/13 |
SUPPL-18(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2019/05/02 |
SUPPL-19(补充) |
Approval |
Labeling |
STANDARD
;Orphan
|
|
|
2019/02/01 |
SUPPL-17(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2016/06/13 |
SUPPL-14(补充) |
Approval |
Labeling |
STANDARD
;Orphan
|
|
|
2014/04/23 |
SUPPL-13(补充) |
Approval |
Efficacy |
PRIORITY
;Orphan
|
|
|
2013/12/19 |
SUPPL-10(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2013/12/19 |
SUPPL-9(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2013/11/22 |
SUPPL-12(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2013/01/23 |
SUPPL-7(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2008/06/20 |
SUPPL-1(补充) |
Approval |
Manufacturing (CMC) |
N/A
|
|
|
2007/12/13 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
PRIORITY
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:SAPROPTERIN DIHYDROCHLORIDE 剂型/给药途径:TABLET;ORAL 规格:100MG 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
022181 |
001 |
NDA |
KUVAN |
SAPROPTERIN DIHYDROCHLORIDE |
TABLET;ORAL |
100MG |
Prescription |
Yes |
Yes |
AB |
2007/12/13
|
BIOMARIN PHARM |
207200 |
001 |
ANDA |
SAPROPTERIN DIHYDROCHLORIDE |
SAPROPTERIN DIHYDROCHLORIDE |
TABLET;ORAL |
100MG |
Prescription |
No |
No |
AB |
2019/05/10
|
ENDO OPERATIONS |
207685 |
001 |
ANDA |
SAPROPTERIN DIHYDROCHLORIDE |
SAPROPTERIN DIHYDROCHLORIDE |
TABLET;ORAL |
100MG |
Prescription |
No |
No |
AB |
2021/06/15
|
DR REDDYS |
215534 |
001 |
ANDA |
SAPROPTERIN DIHYDROCHLORIDE |
SAPROPTERIN DIHYDROCHLORIDE |
TABLET;ORAL |
100MG |
Prescription |
No |
No |
AB |
2022/08/23
|
ANNORA PHARMA |